Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Alzheimers Dement. Author manuscript; available in PMC 2012 March 13.
Published in final edited form as:
PMCID: PMC3299979

Neuropsychiatric symptoms in Alzheimer’s disease


Neuropsychiatric symptoms (NPS) are core features of Alzheimer’s disease and related dementias. Once thought to emerge primarily in people with late-stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment. Despite decades of research, reliable treatments for dementia-associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications. An Alzheimer’s Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer’s disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.

Keywords: Geriatric neuropsychiatric symptoms, Alzheimer’s disease, Mild cognitive impairment, Neuropsychiatric symptom management, Executive dysfunction syndrome

1. Introduction

Although Alzheimer’s disease (AD) is usually considered a cognitive disorder, almost all people diagnosed with AD develop neuropsychiatric symptoms (NPS) at some stage during their disease. Population-based studies show that the frequency of NPS is much higher in people with AD and mild cognitive impairment (MCI) than in the general population [1,2]. Of all the NPS, depression and apathy are the most frequently observed symptoms in people with MCI and early AD, although the incidence of verbal and physical agitation is also high across all stages of MCI and AD. As the disease progresses, delusions, hallucinations, and aggression become more common, whereas apathy is the most persistent and frequent NPS throughout all the stages of AD. Additionally, circadian sleep-wake rhythms become exaggerated as compared with the phase shifts associated with normal aging. The prognostic significance of NPS in the dementing process of AD should not be underestimated. People with MCI progress to AD at a much higher rate if they have depression, whereas those with mild behavioral impairment are more likely to develop dementia even if they have normal cognition [3], and agitation, apathy, anxiety, disinhibition, euphoria, and irritability may have stronger associations with incident MCI than depression [4].

NPS are also associated with major adverse effects on daily function, quality of life, and reduced time to institutionalization. Therefore, NPS also have a major adverse effect on caregivers [5].

How should NPS be identified, classified, and treated? Because individual NPS often cluster together and may overlap across symptom clusters, it has been challenging to delineate clear syndromes. However, across different populations and using factor and cluster analytic methods, several syndromes appear fairly consistently and deserve further research. These most often include depression, psychosis, apathy, hyperactivity/agitation, sleep disorders, and prefrontal syndromes. It is important to gain more clarity regarding these syndromes because their phenotype may help to delineate the underlying neural regions and circuitry, and thereby shed light on neuropathogenesis. Consequently, insight into the neuropathogenesis, which may be distinct from the brain regions underlying language and memory deficits of AD, can be gained. Whether some persons are more susceptible to exhibit certain NPS related to their genetics, medical comorbidities, or lifestyle choices, or whether these are more related to the level of involvement of certain neurotransmitter systems or anterior (e.g., frontolimbic) brain regional atrophy and disconnection is unknown. Limited translational research into NPS suggests that all of the above may play a role. Further understanding of these biological underpinnings offers an opportunity to develop more targeted drug treatments and nonpharmacological management techniques that enhance caregiver coping skills. The focus of this article is on the translational biological parameters that could assist in understanding and treating NPS syndromes of AD and MCI.

2. Phenotype measurement

With the exception of “Psychosis of AD” [6] and “Depression of AD” [7,8], there are few consensus diagnostic criteria for NPS in dementia. Ensuring that these symptoms occur specifically in the context of the AD process is important to distinguish them from other causes such as comorbid or preexisting psychiatric disorders. There are also numerous methodological issues to consider when evaluating NPS in the context of dementia, including participant population (controls, MCI, or AD), study duration, frequency of assessment, desired outcome of a particular study (symptom reduction, secondary prevention/delayed onset of psychopathology, or primary prevention), and use of informants (which can introduce bias). Validated scales in widespread use fall into two categories: focused scales—for example, scales for depression or agitation—and general scales, including the Neuropsychiatric Inventory (NPI), that assess more than one NPS domain [9]. In general, the type of instruments used depends on the specific study objectives.

Although the NPI is the most widely used NPS measure, it has some drawbacks. Subscales that have not yet been validated are commonly used in studies. Also, it is based on caregiver input obtained during a clinical interview and does not allow the clinician’s judgment to be factored into the assessment. The Neuropsychiatric Inventory Clinician (NPI-C) Rating was developed in part to address such shortcomings. It is based on observable and behavioral data and is specific to people with dementia [10]. The NPI-C was developed after a comprehensive review of 19 existing NPS measures that produced new NPI items sorted into existing NPI domains. Aberrant vocalization was added as a new domain, whereas the agitation/aggression domain of the original NPI was split to arrive at a total of 14 domains for the NPI-C [11]. Unlike the NPI, each domain and potentially each subquestion within a domain can be rated on the NPI-C. Caregiver and patients rate frequency, severity, and distress of each item, and the clinician provides an overall rating based on interviews and additional chart information, which brings additional strength to the measure when compared with the original.

NPI-C was field tested in an international validation study and compared with focused scales to determine convergent validity. It was trimmed to 142 items (61 more than the NPI) and has been translated into several European languages [11]. The revised NPI-C can be used to rate single or multiple domains and maintains the main advantages of the NPI, including speed and ease of administration and the ability to compare across trials and sites.

3. Clinical phenomenology and pathophysiology

Delusions have been associated with an increase in muscarinic receptors in the orbitofrontal cortex. Fluorodeoxyglucose positron emission tomography (PET) analysis has revealed correlations between delusions and reduced glucose metabolism in the right frontal region of the brain [12]. Many challenges remain to identifying pathologic correlates, not least of which is the complication of the underlying neurodegeneration and the multiple pathologies and symptoms often seen in single cases. For example, poor insight increases the likelihood of delusions in persons with dementia. In fact, fluorodeoxyglucose PET studies suggest overlap between brain regions demonstrating reduced metabolism during episodes of delusions and poor insight. Altered glucose metabolism as measured by PET has also been associated with anxiety, apathy, agitation, and disinhibition in AD, with multiple brain regions involved [1315]. The picture that emerges is that the underlying pathology for NPS is predominantly cortical. Although some symptoms can be linked to specific regions of the brain, others are associated with broader metabolic changes.

New PET imaging ligands for specific brain receptors might help to identify specific dysfunctional networks that contribute to individual NPS. For example, dopamine receptor availability is higher in people with AD/MCI who also have delusions and poor cholinergic binding, and is correlated with NPS, including blunted affect and emotional withdrawal [16]. Interestingly, in one study, cholinesterase inhibitor treatment increased metabolic rate and was associated with reduced NPS [17].

Many challenges exist to a better understanding of the pathology that underlies NPS. Future pathological studies require prospective assessment, larger numbers of volunteers, standardized assessments, and multimodal brain imaging analysis. There is a need to develop centers of excellence to examine NPS across all levels of discovery: etiology, pathogenesis, pathology, pathophysiology, and clinical disease. The overarching principles that are to be considered for studies of NPS in AD are course, context, and convergence: symptoms may change over the course of the disease (e.g., psychosis is more common in mid to late stages); symptoms may differ depending on the underlying cause (e.g., vascular damage, plaque burden, inflammation, tau pathology); and convergence may be important because the same symptoms or syndromes may be rooted in different pathophysiologies.

4. Classification and differentiation

There are two main clinical purposes to appropriately classify and characterize NPS in AD. One is to allow a diagnosis of AD versus other diseases. The second is to identify subgroups of individuals with AD. NPS and their syndromes in AD can have phenotypic characteristics that help to distinguish them from other psychiatric disorders. For example, the types of delusional content or hallucinations differ from schizophrenia. Further, the symptom pattern may be differentiated to some degree from other types of dementias, for example, frontotemporal degeneration, in which euphoria is more common than in AD.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) III classified dementia as a primary diagnosis with subclassifications based on the presence of delirium or delusions [18]. It also noted that people may undergo personality changes, including becoming apathetic, withdrawn, paranoid, and/or irritable. DSM-IV also subclassified AD and other dementias based on behavior, including delirium, delusions, and behavior problems [19]. A text revision of DSM-IV listed AD as simply being with or without behavioral disturbance. DSM-V is currently being drafted and is due to be published in 2013. The current draft proposes two broad categories, tentatively named Major and Minor (or Mild) Neurocognitive Disorder. The “major” category will subsume dementias, including AD, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and so forth. The “minor” (or mild) category will include neurocognitive impairment that does not reach the threshold of dementia and includes MCI of AD, as well as other disorders, not all necessarily progressive in nature. The DSM-V workgroup is currently discussing how to designate neuropsychiatric disturbances within this framework. Alternatives being discussed include specific subtypes of AD with various behavioral disturbances versus separate entities such as psychosis of AD (PAD) and depression of AD.

Two criteria that may help further classify NPS are central nervous system and peripheral biomarkers and genetic polymorphisms. At present, a range of ligands is available for imaging neurotransmitter receptors and assessing receptor occupancy in vivo. Molecular imaging of other psychiatric disorders, for example, schizophrenia and depression, suggests that receptor availability/occupancy alone cannot distinguish people with the disease from controls, but dynamic measures or interactions between measures may be informative [20]. For example, changes in glucose metabolism in response to treatment with antidepressants predict treatment outcome, as does an increase in serotonin transporter occupancy [21]. Going forward, it will be informative to look at biomarkers in nondemented controls and persons with MCI/AD with and without NPS. Biomarker analyses should also be combined with markers of drug response to understand the impact of NPS on dementia risk and progression.

Genotyping may help develop predictive models of who is at risk for NPS. Genetics may also help with nosology by shifting classification from phenomenology to etiology to help understand the latter. Currently, not much is known about the genetics of NPS in dementia, but association studies suggest that there is some degree of heritability in psychosis and depression [22,23]. Positive associations have been found for various neurotransmitter pathway genes, for example, although the data are often equivocal [2426]. Going forward, large sample sizes of people with a diagnosis of AD who manifest NPS will be needed to identify genetic risk loci. It is likely that the genetic architecture of NPS in dementia will be polygenic with both common variants of small effect and rare variants of larger effect size.

5. NPS in prodromal AD

Several studies have reported that NPS are common in people diagnosed with MCI in a clinical setting [27]. More recently, data from the Mayo Clinic Study of Aging confirmed that the same is true for population-based samples. The study looked at >300 MCI cases and > 1500 controls, and found significant differences between MCI and controls on the presence of agitation, anxiety, apathy, delusions, depression, disinhibition, and irritability, as judged by the NPI. In this setting, differences in apathy, anxiety, irritability, and depression most clearly distinguished between those with MCI from controls [2]. Additionally, Geda et al from Mayo Clinic Rochester conducted an exploratory analysis of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data examining the correlations between the Neuropsychiatric Inventory–Questionnaire (NPI-Q) scores and Pittsburgh compound B (PiB) binding [28]. After adjusting for age, sex, and education, a weak correlation was found between Global 11C-PiB-PET retention and total NPI-Q scores (r = 0.23 [0.03–0.41]), but significance was lost after adjusting for Mini-Mental State Examination (r = 0.13 [−0.07 to 0.320]) [29]. Similarly, there were weak correlations between regional 11C-PiB-PET retentions (prefrontal, temporal, and parietal) and total NPI scores that dissipated when adjusting for the Mini-Mental State Exam.

Longitudinal incidence and interventional studies could address whether normal elderly persons with NPS are more at risk for developing MCI and whether treating those symptoms might prevent or delay progression to MCI and dementia. Several studies have addressed the impact of NPS on progression to dementia in persons diagnosed with MCI and in controls [30,31]. Although the results are mixed, there are indications that the presence of behavioral symptoms may increase the risk of dementia. These findings are supported by recent analysis of a much larger sample set from the National Alzheimer’s Disease Coordinating Center database, which has more than 3600 participants diagnosed with MCI [32]. The data indicate that NPS, as judged by the NPI-Q, are associated with a higher risk of dementia in general, and also a higher risk for AD and frontotemporal degeneration. Specifically, in this MCI cohort, when delusions, agitation, and depression are noted on their respective NPI-Q subdomains, there is a more rapid progression to dementia.

Studying NPS in MCI could provide a basis for understanding how NPS change and evolve as dementia progresses. The Development of Screening Guidelines and Criteria for Predementia Alzheimer’s disease study is a European collaborative to develop screening guidelines and clinical criteria for early diagnosis of AD [33]. It is a prospective, multicenter cohort study that has enrolled more than 800 subjects with MCI who were reassessed at 3-year follow-up postbaseline. Approximately 20% progressed to dementia. The data suggest that anxiety may be a risk factor for AD progression. Anxiety was also associated with abnormal cerebral spinal fluid levels of Aβ42 and total tau [34]. The data for other NPI domains were not as convincing; however, there are indications of interactions with comorbidities. In the Cognitive Function and Ageing Study in Britain, neither depression alone nor high blood pressure was a risk factor for dementia, but combining these variables was associated with a 2.5 increased risk for dementia [35]. Depression was also closely related to cognition in the Maastricht Aging Study, as were white matter lesions in a late-life depression cohort in Newcastle, UK. The data suggest that there may be an interaction between depression and vascular pathology in affecting cognitive decline and progression to dementia.

Other studies have shown that the combination of depression and/or apathy with diabetes increases risk for dementia. Incorporating the presence of depression, apathy, or other NPS into revised diagnostic criteria for AD is worth considering. Treating these symptoms might also delay progression of dementia. Psychotropic agents, for example, affect signaling pathways and may enhance neurotrophic and neuroprotective mechanisms in the brain. Although antipsychotic agents may not be the best choice because they have been found to be detrimental to some people with dementia, most antidepressants are relatively safe. Data also suggest that both galantamine and memantine treatment delay deterioration on the NPI total score and on specific NPI subdomains in people with cognitive impairment [3639]. The data suggest that NPS may not only be risk factors but may also be markers of disease progression.

6. Efficacy trials and nonpharmacological approaches to NPS management

There is a long history of treatment for NPS in neurological conditions, starting with penicillin for encephalitis and culminating in the more recent atypical antipsychotic drugs. Many different treatments have been tested in dementia. Recent antipsychotic trials in dementia have followed a similar model, evaluating from 6 to 12 weeks of treatment with a placebo arm for comparison. They have all ended similarly, with, at best, a small improvement over placebo. Risperidone, for example, shows an improvement in psychosis in the Behavioral Pathology in Alzheimer’s Disease Rating Scale [39], but only slightly more so than placebo. Other antipsychotics have similar outcomes or are negative. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer’s Disease study [40] demonstrated that these drugs have little effect overall versus placebo. In fact, they are equally likely to harm people with dementia as to help them. The dementia antipsychotic withdrawal trial found no significant efficacy for drug versus placebo, thereby suggesting that people do not need to be maintained on antipsychotics [41].

Studies suggest that there are potential benefits from nonpharmacological treatment of NPS in dementia. Targeting environmental and underlying medical triggers may help to attenuate behavioral symptoms. There is good evidence, for example, that music can reduce agitation during bathing. Exercise and pleasant experiences can reduce depression, and activity can reduce the need for restraints in agitated persons. However, most such studies have been of short duration with small sample and effect sizes [42]. Larger randomized trials have found that family caregiver training can improve behavior in people with AD [43]. But how nonpharmacological treatment relates to pathology is still unclear. For example, people may suffer less stress because their capabilities have been realigned. There is a need to further study the relationships between dementia, dementia subtypes, and behavioral treatments.

7. Steps to develop treatments for specific syndromes

Sleep disorders are among one of the most common behavioral disturbances in persons with AD, with 25% to 50% having major sleep problems and almost 75% sleeping for extended periods during the day [44]. Sleep disturbances cause excessive caregiver burden and have a negative impact on cognition and social isolation on both the caregiver and person affected by dementia [45]. Measuring sleep disturbance can be difficult. Caregiver reports are often unreliable, and polysomnography measurements in a laboratory setting are not simple to perform. Ambulatory devices are becoming more widely available, although they may not give information about sleep stages [46]. Light therapy to entrain the biological clock has proven to be beneficial in randomized, controlled trials by improving nighttime sleep and reducing daytime sleep [47,48]. Melatonin has not been found to be useful [49]. Cognitive behavioral therapy for insomnia also reduces nighttime wakefulness [50].

Agitation/aggression is a common behavioral symptom of AD. It is clinically significant in approximately 20% of people with dementia in a community setting and in nearly 50% of people in care facilities [1]. The first line of treatment should always be to remove the source of the agitation whenever possible. Psychological and social treatments, like music, massage therapy, or caregiver education, might work, but medication may be necessary in more extreme cases. Although antipsychotics have modest benefits, they also have serious adverse effects, such as increased risk of cerebrovascular events and mortality. Carbamazepine demonstrated significant benefits in three small trials, but valproate has not proven useful. The antidepressant citalopram has been shown to be as effective as risperidone [51], an atypical antipsychotic, in the treatment of agitation. Several other antidepressants were not found to be useful for agitation [52]. Fewer people on memantine develop agitation [53]. Because it is not clear whether the drug helps those who are already agitated or prevents people from becoming agitated, ongoing trials are awaited. Future studies should focus on psychosocial interventions for less severe agitation, short-term medication for the most severe cases, and combinations of the two, or sequential algorithms for most participants.

Diagnosing and treating depression in patients with AD is complicated. There is often considerable overlap with apathy and late-life depression unrelated to AD [54,55]. Latent class analysis, which is a model-based clustering approach that characterizes heterogeneity in symptom profiles at the patient level, may prove useful in diagnosing depression in AD patients [56,57]. A recent meta-analysis suggests that antidepressants do not have strong effects on late-life depression [58]. Similarly, the Depression in Alzheimer’s Disease Study–2 trial did not find a positive effect of sertraline for depression in AD [59,60]. The efficacy of selective serotonin reuptake inhibitors for depression in Parkinson’s disease has not been established either. However, treatments such as tricyclic antidepressants and a dopamine agonist (pramipexole) have shown some efficacy in treating depression in Parkinson’s disease [61,62]. Looking forward, there are pathologies that could reveal potential targets for treating depression in AD. Neuropathology in monoamingergic networks may be related to depression [63], as may the number of corticotropin-releasing hormone neurons in the hypothalamus [64]. Biomarker analysis and associated genetic polymorphisms might also shed some light on the depression in AD. The finding that small hippocampal volume in late-life depression predicts subsequent dementia indicates that brain imaging may also be useful [65].

Psychoses are common in AD patients. Although some are mild and run their natural course without causing much stress, others, such as delusions, can be serious and a danger to both persons with the disease and caregivers [6668]. Whether and when the physician should begin treatment depends on the frequency and severity of symptoms. The drugs currently used to treat psychoses in dementia, atypical antipsychotics, have limited efficacy (see earlier in the text) and should only be used as a last resort [52]. Treating any of these heterogeneous symptoms is likely to lead to only modest overall effect. A much better understanding of the pathophysiology of psychosis in dementia is needed.

Apathy is the most common and persistent NPS in AD patients [1,69]. It is defined as diminished motivation for at least 4 weeks, accompanied by any two of the following: reduced goal-directed behavior, reduced goal-directed cognitive activity, and reduced emotions [70]. Because these diagnostic criteria were newly formulated in 2009, assessment instruments are still being refined. Overlap between apathy and executive dysfunction has emerged in many studies [7173], which may help to shed light on underlying causality because both are related to dysfunction of thalamic-prefrontal-subcortical circuitry. Donepezil has been shown to reduce apathy in people with moderate to severe AD [74]. Methylphenidate has shown efficacy in several small uncontrolled trials [7579] and one controlled trial [80], and is being followed up in a larger trial of 60 participants. Various other drugs (including amantadine, d-amphetamine, and modafinil) have shown mixed results [81]. Selective serotonergic reuptake inhibitors may contribute to apathy. One challenge for the field is the relative paucity of trials targeting apathy in dementia. As with many NPS, imaging data may help pinpoint areas of the brain that are affected [82]. Apathy in AD is associated with gray matter atrophy in the anterior cingulate cortex and the left supplementary motor area [83,84]. People with AD and apathy also have more white matter hyperintensities [71,85] and a mixed pattern of reduced and elevated blood flow in different regions, thereby suggesting that the brain may be trying to compensate for the reduced blood flow. People with dementia and apathy also show a blunted response to d-amphetamine [86], suggesting problems with the brain reward system. Better appreciation of phenomenology, neuroimaging, and pharmacology might help optimize treatment approaches for apathy in dementia.

Not infrequent NPS occurring in those with more severe dementia are disinhibited and aggressive behaviors that appear to result from loss of executive control of behavior, sometimes referred to as executive dysfunction syndrome [87]. When it occurs, executive dysfunction syndrome is another potential target for treatment, although specific diagnostic criteria for executive dysfunction syndrome in dementia are needed. Executive dysfunction syndrome often manifests in people who have suffered acute brain damage affecting frontal-subcortical loop functioning, but it also emerges in people with degenerative cognitive impairment [87,88]. It is characterized by executive cognitive deficits, emotional apathy, inattention, excessive and inappropriate jocularity, social inappropriateness, and impulsivity [89]. Relevant domains on the NPI-C include disinhibition, aberrant motor behavior, aberrant vocalizations, and aggression [10]. Disturbances in any of three specific “behavioral” neuronal circuits originating in frontal cortex might contribute to executive dysfunction syndrome. These circuits can be modulated by ascending neurotransmitter tracts, including dopaminergic, noradrenergic, acetylcholinergic, and serotonergic inputs, any of which might prove useful targets for treatment [87]. Dopamine augmentation, for example, relieved perseveration behavior in a small number of people with dementia [90], and amantadine has also been used in a small number of people for the same purpose [91]. Study of the pathophysiology and brain imaging should also shed light on the neuropathogenesis of executive dysfunction syndrome.

8. Funding and regulatory issues

The lack of consensus about how to define NPS in AD has been an obstacle to drug development. Historically, the construct “behavioral and psychological symptoms of dementia (BPSD)” was suggested as a target for drug development in people with dementia with NPS, but this was considered too broad a categorization by the U.S. Food and Drug Administration (FDA) [52]. Focusing on specific NPS syndromes in AD has been considered a better approach. From the March 2000 meeting of the FDA Psychopharmachological Drugs Advisory Committee, some consensus emerged on “Psychosis of Alzheimer’s disease” as a distinct entity [6]. However, there was limited consensus on how to define agitation as a possible target.

Defining other syndromes of AD should be a focus of future work. DSM criteria are not needed for the FDA Division of Psychiatric Products to endorse a clinical entity for drug development. Rather, the entity must be sufficiently well characterized, such that it can be studied and described in labeling, and be attributable to AD. It should also be reasonably well accepted in the clinical/academic community and distinguishable from recognized clinical entities in other settings. PAD is the only target formally endorsed by the FDA [92].

The FDA would beam enable to carving out additional NPS targets by combining signs and symptoms into distinct entities for drug development. The challenge would be making the case that a particular cluster of symptoms is a well-defined and distinct entity. It would also have to have acceptance in the clinical/academic community. For example, to demonstrate that depression associated with MCI is distinct from other types of depression, it would have to be shown that the phenomenology, course, and response to treatment are different than for other types of depression.

The FDA has required a co-primary outcome measure in AD trials. A greater distinction regarding PAD has to be made. The agency is, however, willing to consider arguments against this stipulation, but with caution. Other aspects of study design would depend on the specific entity being targeted.

9. Conclusions and recommendations

Regarding assessment of NPS in AD, any new NPS tools would need to be developed with standard methodology and to be shown to have at least face validity. An acceptable key secondary measure would be one that targets a separate domain, for example, improved functional capacity, rather than simply replicating the primary symptom domain assessed by the primary measure.

NPS could qualify as a secondary outcome in a disease modification trial, but this assumes that a single drug targets both cognitive and behavioral symptoms, which may not be realistic. A better approach might be to use time to NPS emergence as an endpoint in trials targeting specific NPS.

Currently, there are very few medications that are useful for NPS in patients with AD. Antipsychotics are perhaps the most widely used for NPS, but their efficacy is modest at best, and the potential for serious side effects remains a concern. Key questions that are emerging include the following: Can the assessment of NPS be improved? Are neuropsychiatric conditions risk factors for dementia such that targeting them might reduce dementia risk? Do these syndromes or their successful treatment modify the course of dementia? What is the efficacy and safety of existing treatments? And can safer, more efficacious drugs be developed?


The Neuropsychiatric Symptoms in Alzheimer’s Disease Subcommittee of the Alzheimer’s Association Research Roundtable thanks all speakers who participated in this meeting, including Clive Ballard, MD; Neil Buckholtz, PhD; Paul Francis, PhD; Mary Ganguli, MD; Serge Gauthier, MD; Yonas Geda, MD; Laura Gitlin, PhD; Russell Katz, MD; Krista Lanctot, PhD; Thomas Laughren, MD; Gill Livingston, MD; Constantine Lyketsos, MD; Jennifer Martin, PhD; Kate de Medeiros, PhD; Paul Rosenberg, MD; Lon Schneider, MD; Gwenn Smith, PhD; David Sultzer, MD; Robert Sweet, MD; Pierre Tariot, MD; Frans Verhey, MD, PhD; Philip Wang, MD; Dan Weintraub, MD; Peter Zandi, PhD. The efforts of C.G.L. on this project were supported in part by the Johns Hopkins Alzheimer’s Disease Research Center, grant P50AG005146. The authors also thank Tom Fagan (Science Writer) and DeLois Powe (Alzheimer’s Association) for their assistance in preparing this manuscript.


1. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, Dekosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475–1483. [PubMed]
2. Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJ, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65:1193–1198. [PMC free article] [PubMed]
3. Taragano FE, llegri RF, Krupitzki H, Sarasola DR, Serrano CM, Lon L, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70:584–592. [PMC free article] [PubMed]
4. Geda YE, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: the mayo clinic study of aging; AAN Annual Meeting; Honolulu, Hawaii. 2011.
5. Allegri RF, Sarasola D, Serrano CM, Taragano FE, Arizaga RL, Butman J, et al. Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2006;2:105–110. [PMC free article] [PubMed]
6. Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29–34. [PubMed]
7. Lyketsos CG, Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52:243–252. [PubMed]
8. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer’s disease: a practical update for the clinician. Dement Geriatr Cogn Disord. 2004;17:55–64. [PubMed]
9. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–S16. [PubMed]
10. Steinberg M, Lyketsos CG. Neuropsychiatric measures for cognitive disorders. In: Rush AJ, First MB, Blacker D, editors. Handbook of Psychiatric Measures. Arlington, VA: American Psychiatric Publishing; 2008. p. 864.
11. de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22:984–994. [PMC free article] [PubMed]
12. Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer’s disease. Am J Psychiatry. 2003;160:341–349. [PubMed]
13. Hashimoto H, Monserrat L, Nguyen P, Feil D, Harwood D, Mandelkern MA, et al. Anxiety and regional cortical glucose metabolism in patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2006;18:521–528. [PubMed]
14. Marshall GA, Monserrat L, Harwood D, Mandelkern MA, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64:1015–1020. [PubMed]
15. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1995;7:476–484. [PubMed]
16. Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009;72:528–534. [PMC free article] [PubMed]
17. Mega MS, Cummings JL, O’Connor SM, Dinov ID, Reback E, Felix J, et al. Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:63–68. [PubMed]
18. Diagnostic and statistical manual of mental disorders. 3rd revised ed. Washington, DC: American Psychiatric Association; 1987.
19. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2000.
20. Lyketsos CG, Szekely CA, Mielke MM, Rosenberg PB, Zandi PP. Developing new treatments for Alzheimer’s disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr. 2008;20:871–889. [PMC free article] [PubMed]
21. Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, Chaly T, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009;66:259–266. [PMC free article] [PubMed]
22. DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer’s disease: a review. J Alzheimers Dis. 2010;19:761–780. [PMC free article] [PubMed]
23. Sweet RA, Bennett DA, Graft-Radford NR, Mayeux R. National Institute on Aging Late-Onset Alzheimer’s Disease Family Study Group. Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s Disease Family Study. Brain. 2010;133(Pt 4):1155–1162. [PMC free article] [PubMed]
24. Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009;17:839–846. [PubMed]
25. Borroni B, Grassi M, Constanzi C, Zanetti M, Archetti S, Franzoni S, et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging. 2007;28:1231–1238. [PubMed]
26. Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms inAlzheimer’s disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett. 2004;368:33–36. [PubMed]
27. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004;18:17–21. [PubMed]
28. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–239. [PubMed]
29. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. [PubMed]
30. Edwards ER, Spira AP, Barnes DE, Yaffe K. Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia. Int J Geriatr Psychiatry. 2009;24:716–722. [PMC free article] [PubMed]
31. Moretti DV, Frisoni GB, Fracassi C, Pievani M, Geroldi C, Binetti G, et al. MCI patients’ EEGs show group differences between those who progress and those who do not progress to AD. Neurobiol Aging. 2011;32:563–571. [PubMed]
32. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leotsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26:364–372. [PMC free article] [PubMed]
33. Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, et al. Development of screening guidelines and clinical criteria for pre-dementia Alzheimer’s disease. The DESCRIPA Study. Neuroepidemiology. 2008;30:254–265. [PMC free article] [PubMed]
34. Visser PJ, Verhey FR, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619–627. [PubMed]
35. Kohler S, van Boxtel MP, van Os J, Thomas AJ, O’Brien JT, Jolles J, et al. Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc. 2010;58:873–879. [PubMed]
36. Herrmann N, Rabheru K, Wang J, Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005;13:527–534. [PubMed]
37. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEMMD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–89. [PubMed]
38. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis inmoderately severe to severeAlzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341–348. [PubMed]
39. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. Risperidone for psychosis of Alzheimer’s disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20:1153–1157. [PubMed]
40. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–1538. [PubMed]
41. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151–157. [PubMed]
42. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996–2021. [PubMed]
43. Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58:1465–1474. [PMC free article] [PubMed]
44. David R, Zeitzer J, Friedman L, Noda A, O’Hara R, Robert P, et al. Non-pharmacologic management of sleep disturbance in Alzheimer’s disease. J Nutr Health Aging. 2010;14:203–206. [PubMed]
45. Lee DR, Thomas AJ. Sleep in dementia and caregiving–assessment and treatment implications: a review. Int Psychogeriatr. 2011;23:190–201. [PubMed]
46. McCurry SM, Pike KC, Vitiello MV, Logsdon RG, Teri L, et al. Factors associated with concordance and variability of sleep quality in persons with Alzheimer’s disease and their caregivers. Sleep. 2008;31:741–748. [PubMed]
47. Most EI, Scheltens P, van Someren EJ. Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light–a randomized clinical trial. Trials. 2010;11:19. [PMC free article] [PubMed]
48. Burns A, Allen H, Tomenson B, Duignan D, Byrne J. Bright light therapy for agitation in dementia: a randomized controlled trial. Int Psychogeriatr. 2009;21:711–721. [PubMed]
49. Gehrman PR, Connor DJ, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry. 2009;17:166–169. [PMC free article] [PubMed]
50. Fiorentino L, Martin JL. Awake at 4 AM: treatment of insomnia with early morning awakenings among older adults. J Clin Psychol. 2010;66:1161–1174. [PMC free article] [PubMed]
51. Ownby RL. Citalopram versus risperidone for behavioral problems in dementia. Curr Psychiatry Rep. 2008;10:8–9. [PubMed]
52. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5:245–255. [PubMed]
53. Herrmann N, Cappell J, Eryavec GM, Lanctot KL. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer’s disease: an open-label pilot study. CNS Drugs. 2011;25:425–433. [PubMed]
54. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:125–128. [PubMed]
55. Starkstein SE, Ingram L, Garau ML, Mizrahi R. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry. 2005;76:1070–1074. [PMC free article] [PubMed]
56. Ownby RL, Acevedo A, Harwood DG, Barker WW, Duara R. Patterns of depression in Spanish- and English-speaking patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2008;21:47–55. [PubMed]
57. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043–1053. [PubMed]
58. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16:558–567. [PubMed]
59. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136–145. [PMC free article] [PubMed]
60. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332–340. [PMC free article] [PubMed]
61. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886–892. [PMC free article] [PubMed]
62. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–580. [PubMed]
63. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol. 1990;47:209–214. [PubMed]
64. Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJ. Relation between corticotropin-releasing hormone neuron number in the hypothalamic paraventricular nucleus and depressive state in Alzheimer’s disease. Neuroendocrinology. 2007;85:37–44. [PubMed]
65. Steffens DC, Payne ME, Greenberg DL, Byrum CE, Welsh-Bohmer KA, Wagner HR, et al. Hippocampal volume and incident dementia in geriatric depression. Am J Geriatr Psychiatry. 2002;10:62–71. [PubMed]
66. Ballard CG, Eastwood C, Gahir M, Wilcock G. A follow up study of depression in the carers of dementia sufferers. Br Med J. 1996;312:947. [PMC free article] [PubMed]
67. Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry. 1999;156:1039–1045. [PubMed]
68. Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry. 2001;62:631–636. [PubMed]
69. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130–135. [PubMed]
70. Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24:98–104. [PubMed]
71. Jonsson M, Edman A, Lind K, Rolstad S, Sjogren M, Wallin A. Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia. Int J Geriatr Psychiatry. 2010;25:588–595. [PubMed]
72. Nakaaki S, Murata Y, Sato J, Shinagawa Y, Hongo J, Tatsumi H. Association between apathy/depression and executive function in patients with Alzheimer’s disease. Int Psychogeriatr. 2008;20:964–975. [PubMed]
73. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer’s disease. J Int Neuropsychol Soc. 2002;8:373–381. [PubMed]
74. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14:389–404. [PubMed]
75. Maletta GJ, Winegarden T. Reversal of anorexia by methylphenidate in apathetic, severely demented nursing home patients. Am J Geriatr Psychiatry. 1993;1:10.
76. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997;9:231–239. [PubMed]
77. Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH. Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001;49:474–476. [PubMed]
78. Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci. 2007;19:81–83. [PubMed]
79. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18:371–374. [PubMed]
80. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28:296–301. [PubMed]
81. Mitchell RA, Herrmann N, Lanctot KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther. (in press) [PubMed]
82. Lanctot KL, Moosa S, Herrmann N, Leibovitch FS, Rothenburg L, Cotter A, et al. A SPECT study of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24:65–72. [PubMed]
83. Tunnard C, Whitehead D, Hurt C, Wahlund LO, Mecocci P, Tsolaki M, et al. Apathy and cortical atrophy in Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26:741–748. [PubMed]
84. Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, et al. Structural correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24:91–97. [PubMed]
85. Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD. Neuroimaging correlates of apathy and depression in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2009;21:259–265. [PubMed]
86. Lanctot KL, Herrmann N, Black SE, Ryan M, Rothenburg LS, Liu BA, et al. Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry. 2008;16:551–557. [PubMed]
87. Lyketsos CG, Rosenblatt A, Rabins P. Forgotten frontal lobe syndrome or “Executive Dysfunction Syndrome” Psychosomatics. 2004;45:247–255. [PubMed]
88. Drayton SJ, Davies K, Steinberg M, Leroi I, Rosenblatt A, Lyketsos CG. Amantadine for executive dysfunction syndrome in patients with dementia. Psychosomatics. 2004;45:205–209. [PubMed]
89. Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000;6:460–468. [PubMed]
90. Imamura T, Takanashi M, Hattori N, Fujimori M, Yamashita H, Ishii K, et al. Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord. 1998;12:109–113. [PubMed]
91. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222–230. [PubMed]
92. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:340–345. [PubMed]